Search results
Your search for XIST returned no results
Showing 61 to 75 of 1556 results for list
Showing 61 to 75 of 1556 results for list
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
Evidence-based recommendations on mirikizumab (Omvoh) for previously treated moderately to severely active Crohn's disease in adults.
Emergency and acute medical care in over 16s: service delivery and organisation (NG94)
This guideline covers organising and delivering emergency and acute medical care for people aged over 16 in the community and in hospital. It aims to reduce the need for hospital admissions by giving advanced training to paramedics and providing community alternatives to hospital care. It also promotes good-quality care in hospital and joint working between health and social services.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
In development Reference number: GID-QS10186 Expected publication date: 19 March 2026
In development Reference number: GID-TA11330 Expected publication date: TBC
Acute upper gastrointestinal bleeding in over 16s: management (CG141)
This guideline covers how upper gastrointestinal bleeding can be effectively managed in adults and young people aged 16 years and older. It aims to identify which diagnostic and therapeutic steps are useful so hospitals can develop a structure in which clinical teams can deliver an optimum service for people who develop this condition.
View recommendations for CG141Show all sections
In development Reference number: GID-TA11298 Expected publication date: TBC
In development Reference number: GID-TA11246 Expected publication date: 05 March 2026
Each year we work with NHSE and the DHSC to prioritise topics for development.
In development Reference number: GID-NG10448 Expected publication date: TBC
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Digital self-help for eating disorders: early value assessment (HTG768)
Early value assessment (EVA) guidance on digital self-help for eating disorders.
patient access schemes? If pharmaceutical company is unable to set an NHS list price that would be considered cost-effective, they can...